心脉医疗（688016）披露2025年第三季度报告，10月30日股价下跌5.14%

Core Points - The stock of Xinmai Medical (688016) closed at 100.0 yuan on October 30, 2025, down 5.14% from the previous trading day, with a total market capitalization of 12.326 billion yuan [1] - The company reported a revenue of 1,014,780,041.62 yuan for the first three quarters of 2025, representing a year-on-year increase of 4.66%, while the net profit attributable to shareholders decreased by 22.46% to 429,055,896.79 yuan [1] - Research and development (R&D) expenses totaled 89,097,024.52 yuan, down 31.60% year-on-year, due to the optimization of the R&D team structure and project commercialization potential assessment [1] - As of September 30, 2025, the company repurchased 1,263,043 shares, accounting for 1.02% of the total share capital, with a total expenditure of 132,745,761.84 yuan [1] - The total assets of the company reached 4,732,362,656.89 yuan, an increase of 10.27% compared to the end of the previous year, while the equity attributable to shareholders grew by 4.35% to 3,956,811,416.72 yuan [1]